A U.S. appeals court on Tuesday ruled that a patent related to Swiss drugmaker Novartis AG's blockbuster multiple sclerosis drug Gilenya was invalid, potentially...
Promomed Group received marketing authorization certificate for a medicinal product with nadroparin calcium as active ingredient. Nadroparin is a low molecular weight heparin. It...
GlaxoSmithKline will be the most affected, as it represents 26% of the potentially impacted drugs. This is followed by Novartis at 14%, Sanofi at 11%, and both Pfizer and Bayer with 8%.